These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. A KRAS variant is a biomarker of poor outcome, platinum chemotherapy resistance and a potential target for therapy in ovarian cancer. Ratner ES; Keane FK; Lindner R; Tassi RA; Paranjape T; Glasgow M; Nallur S; Deng Y; Lu L; Steele L; Sand S; Muller RU; Bignotti E; Bellone S; Boeke M; Yao X; Pecorelli S; Ravaggi A; Katsaros D; Zelterman D; Cristea MC; Yu H; Rutherford TJ; Weitzel JN; Neuhausen SL; Schwartz PE; Slack FJ; Santin AD; Weidhaas JB Oncogene; 2012 Oct; 31(42):4559-66. PubMed ID: 22139083 [TBL] [Abstract][Full Text] [Related]
3. Extensive sequence variation in the 3' untranslated region of the KRAS gene in lung and ovarian cancer cases. Kim M; Chen X; Chin LJ; Paranjape T; Speed WC; Kidd KK; Zhao H; Weidhaas JB; Slack FJ Cell Cycle; 2014; 13(6):1030-40. PubMed ID: 24552817 [TBL] [Abstract][Full Text] [Related]
6. Prevalence of the variant allele rs61764370 T>G in the 3'UTR of KRAS among Dutch BRCA1, BRCA2 and non-BRCA1/BRCA2 breast cancer families. Hollestelle A; Pelletier C; Hooning M; Crepin E; Schutte M; Look M; Collee JM; Nieuwlaat A; Dorssers LC; Seynaeve C; Aulchenko YS; Martens JW; van den Ouweland AM; Weidhaas JB Breast Cancer Res Treat; 2011 Jul; 128(1):79-84. PubMed ID: 20676756 [TBL] [Abstract][Full Text] [Related]
7. TP53 mutations are common in all subtypes of epithelial ovarian cancer and occur concomitantly with KRAS mutations in the mucinous type. Rechsteiner M; Zimmermann AK; Wild PJ; Caduff R; von Teichman A; Fink D; Moch H; Noske A Exp Mol Pathol; 2013 Oct; 95(2):235-41. PubMed ID: 23965232 [TBL] [Abstract][Full Text] [Related]
8. Clinicopathological correlates and prognostic significance of KRAS mutation status in a pooled prospective cohort of epithelial ovarian cancer. Nodin B; Zendehrokh N; Sundström M; Jirström K Diagn Pathol; 2013 Jun; 8():106. PubMed ID: 23800114 [TBL] [Abstract][Full Text] [Related]
9. [Association between single nucleotide polymorphism of BARD1 gene and BRCA1 gene mutation in epithelial ovarian cancer]. Liu WL; Zhao JZ; Wang ZZ; Dong B; Hou YY; Wu XX; Guo YJ Zhonghua Fu Chan Ke Za Zhi; 2017 Jun; 52(6):403-410. PubMed ID: 28647964 [No Abstract] [Full Text] [Related]
10. MicroRNA processing and binding site polymorphisms are not replicated in the Ovarian Cancer Association Consortium. Permuth-Wey J; Chen Z; Tsai YY; Lin HY; Chen YA; Barnholtz-Sloan J; Birrer MJ; Chanock SJ; Cramer DW; Cunningham JM; Fenstermacher D; Fridley BL; Garcia-Closas M; Gayther SA; Gentry-Maharaj A; Gonzalez-Bosquet J; Iversen E; Jim H; McLaughlin J; Menon U; Narod SA; Phelan CM; Ramus SJ; Risch H; Song H; Sutphen R; Terry KL; Tyrer J; Vierkant RA; Wentzensen N; Lancaster JM; Cheng JQ; Berchuck A; Pharoah PD; Schildkraut JM; Goode EL; Sellers TA; Cancer Epidemiol Biomarkers Prev; 2011 Aug; 20(8):1793-7. PubMed ID: 21636674 [TBL] [Abstract][Full Text] [Related]
11. A let-7 microRNA SNP in the KRAS 3'UTR is prognostic in early-stage colorectal cancer. Smits KM; Paranjape T; Nallur S; Wouters KA; Weijenberg MP; Schouten LJ; van den Brandt PA; Bosman FT; Weidhaas JB; van Engeland M Clin Cancer Res; 2011 Dec; 17(24):7723-31. PubMed ID: 21994416 [TBL] [Abstract][Full Text] [Related]
12. Identification of novel candidate biomarkers of epithelial ovarian cancer by profiling the secretomes of three-dimensional genetic models of ovarian carcinogenesis. Lawrenson K; Mhawech-Fauceglia P; Worthington J; Spindler TJ; O'Brien D; Lee JM; Spain G; Sharifian M; Wang G; Darcy KM; Pejovic T; Sowter H; Timms JF; Gayther SA Int J Cancer; 2015 Oct; 137(8):1806-17. PubMed ID: 25204737 [TBL] [Abstract][Full Text] [Related]
13. Evaluation of the Role of the KRAS Gene Polymorphism LCS6 (rs61764370) in Iraqi Women with Ovarian Cancer. Ghazi Jumaa M Arch Razi Inst; 2022 Feb; 77(1):205-211. PubMed ID: 35891756 [TBL] [Abstract][Full Text] [Related]
14. Low MAD2 expression levels associate with reduced progression-free survival in patients with high-grade serous epithelial ovarian cancer. Furlong F; Fitzpatrick P; O'Toole S; Phelan S; McGrogan B; Maguire A; O'Grady A; Gallagher M; Prencipe M; McGoldrick A; McGettigan P; Brennan D; Sheils O; Martin C; W Kay E; O'Leary J; McCann A J Pathol; 2012 Apr; 226(5):746-55. PubMed ID: 22069160 [TBL] [Abstract][Full Text] [Related]
15. ABCB1 (MDR1) polymorphisms and ovarian cancer progression and survival: a comprehensive analysis from the Ovarian Cancer Association Consortium and The Cancer Genome Atlas. Johnatty SE; Beesley J; Gao B; Chen X; Lu Y; Law MH; Henderson MJ; Russell AJ; Hedditch EL; Emmanuel C; Fereday S; Webb PM; ; Goode EL; Vierkant RA; Fridley BL; Cunningham JM; Fasching PA; Beckmann MW; Ekici AB; Hogdall E; Kjaer SK; Jensen A; Hogdall C; Brown R; Paul J; Lambrechts S; Despierre E; Vergote I; Lester J; Karlan BY; Heitz F; du Bois A; Harter P; Schwaab I; Bean Y; Pejovic T; Levine DA; Goodman MT; Camey ME; Thompson PJ; Lurie G; Shildkraut J; Berchuck A; Terry KL; Cramer DW; Norris MD; Haber M; MacGregor S; deFazio A; Chenevix-Trench G Gynecol Oncol; 2013 Oct; 131(1):8-14. PubMed ID: 23917080 [TBL] [Abstract][Full Text] [Related]
16. [Polymorphisms of ERCC1 gene and outcomes in epithelial ovarian cancer patients with platinum-based chemotherapy]. Qi BL; Li Y; Wang N; Zhou RM; Hu P; Kang S Zhonghua Fu Chan Ke Za Zhi; 2013 Nov; 48(11):847-52. PubMed ID: 24444563 [TBL] [Abstract][Full Text] [Related]
18. Genetic polymorphisms in the Fas and FasL genes are associated with epithelial ovarian cancer risk and clinical outcomes. Li Y; Hao YL; Kang S; Zhou RM; Wang N; Qi BL Gynecol Oncol; 2013 Mar; 128(3):584-9. PubMed ID: 23234803 [TBL] [Abstract][Full Text] [Related]
19. The effects of common genetic variants in oncogenes on ovarian cancer survival. Quaye L; Gayther SA; Ramus SJ; Di Cioccio RA; McGuire V; Hogdall E; Hogdall C; Blaakr J; Easton DF; Ponder BA; Jacobs I; Kjaer SK; Whittemore AS; Pearce CL; Pharoah PD; Song H Clin Cancer Res; 2008 Sep; 14(18):5833-9. PubMed ID: 18794094 [TBL] [Abstract][Full Text] [Related]
20. MicroRNA-145 targets TRIM2 and exerts tumor-suppressing functions in epithelial ovarian cancer. Chen X; Dong C; Law PT; Chan MT; Su Z; Wang S; Wu WK; Xu H Gynecol Oncol; 2015 Dec; 139(3):513-9. PubMed ID: 26472353 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]